Steven Leonard Chapman Sells 1,709 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 1,709 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $120.76, for a total value of $206,378.84. Following the completion of the sale, the chief executive officer now owns 194,615 shares of the company’s stock, valued at $23,501,707.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, October 15th, Steven Leonard Chapman sold 4,523 shares of Natera stock. The shares were sold at an average price of $130.40, for a total transaction of $589,799.20.
• On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52.
• On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The stock was sold at an average price of $118.91, for a total transaction of $663,874.53.
• On Monday, July 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The shares were sold at an average price of $102.77, for a total value of $419,712.68.

Natera Stock Down 1.1 %

Shares of NASDAQ:NTRA opened at $118.65 on Thursday. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The stock has a fifty day simple moving average of $123.43 and a two-hundred day simple moving average of $111.03. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $133.54. The stock has a market capitalization of $14.57 billion, a price-to-earnings ratio of -38.03 and a beta of 1.53.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.39. The firm had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. Natera’s quarterly revenue was up 58.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.97) EPS. On average, research analysts anticipate that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Natera by 5.7% during the 4th quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock valued at $687,280,000 after purchasing an additional 588,147 shares during the last quarter. Farallon Capital Management LLC increased its holdings in Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after buying an additional 532,874 shares in the last quarter. First Light Asset Management LLC raised its position in Natera by 295.9% in the 1st quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock worth $60,063,000 after buying an additional 490,822 shares during the last quarter. AQR Capital Management LLC lifted its stake in Natera by 257.6% during the 2nd quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock valued at $70,553,000 after acquiring an additional 469,327 shares during the period. Finally, Nikko Asset Management Americas Inc. purchased a new stake in shares of Natera during the 1st quarter valued at about $33,938,000. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. TD Cowen boosted their target price on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. BTIG Research upped their price objective on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Stephens reaffirmed an “overweight” rating and issued a $125.00 target price on shares of Natera in a research report on Friday, August 9th. Leerink Partners boosted their price target on shares of Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Finally, The Goldman Sachs Group raised their price objective on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $124.44.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.